Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark and correlates with a favorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Aaroe, Ashley, Kurzrock, Razelle, Goyal, Gaurav, Goodman, Aaron M., Patel, Harsh, Ruan, Gordon, Ulaner, Gary, Young, Jason, Li, Ziyi, Dustin, Derek, Go, Ronald S., Diamond, Eli L., Janku, Filip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410131/
https://www.ncbi.nlm.nih.gov/pubmed/36857436
http://dx.doi.org/10.1182/bloodadvances.2022009013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410131/
https://www.ncbi.nlm.nih.gov/pubmed/36857436
http://dx.doi.org/10.1182/bloodadvances.2022009013

Ejemplares similares